Key Takeaways:
- BSX shares dropped over 50% YTD after three guidance cuts in 2026
- Consensus price target of $78 implies 65% upside from current levels
- 27 of 31 analysts rate the stock a buy despite slowing Watchman sales
Back
Boston Scientific falls 50% as analysts see 65% rebound potential
Boston Scientific shares have fallen over 50% year to date after three guidance cuts, creating the widest gap between stock price and analyst targets in the sector.
"The declining usage of Watchman stand-alone procedures is a headwind we didn't fully anticipate," Chief Executive Officer Michael Mahoney said on the company's late-May investor call, citing flat dollar growth expected from the first quarter through the third quarter.
The company initially guided organic sales growth of 10% to 11% in February, down from 19.5% in 2025. Management cut that to a range of 6.5% to 8% in April, then signaled further weakness in May. The Watchman heart implant, once a growth driver for the Marlborough, Massachusetts-based company, now faces slowing procedure volumes that have weighed on the top line.
The selloff has pushed Boston Scientific's forward valuation into the mid-teens, in line with peers Abbott Laboratories and Medtronic. Yet 27 of 31 analysts covering the stock rate it a buy, with a consensus price target of $78 — implying a 65% rebound. The four analysts with hold or sell ratings reflect concern that the Watchman slowdown may persist longer than management expects.
The repeated guidance walkbacks suggest the company is still calibrating demand for its core electrophysiology and interventional cardiology products. The Watchman franchise, which generated roughly $1.5 billion in revenue last year, faces an uncertain trajectory as physicians shift toward alternative stroke-prevention procedures. Boston Scientific's electrophysiology and endoscopy segments continue to post steady growth, providing a partial offset to the cardiology headwinds.
The analyst community remains divided on timing. Bulls argue the selloff is overdone, noting that Boston Scientific's diversified portfolio — spanning cardiac rhythm management, endoscopy, and urology — limits the downside from any single product line. Bears point to the pattern of downward revisions as evidence that management lacks visibility into procedure volumes. The stock's current valuation, roughly 15 times forward earnings, already prices in a prolonged slowdown, leaving room for upside if Watchman stabilizes. The wide spread between the $78 consensus target and the current stock price suggests the market is pricing in a scenario worse than what most analysts expect.
The broader medtech sector has also faced pressure this year, with the S&P 500 Health Care Equipment index declining roughly 10% over the same period. Boston Scientific's 50% drop far exceeds the sector average, reflecting company-specific headwinds rather than a broad industry downturn.
Investors will watch second-quarter results, due in late July, for signs that the sequential decline is bottoming out. A miss could trigger further analyst downgrades and narrow the gap between the stock price and those lofty targets. For holders, the risk-reward hinges on whether management can stabilize guidance — or whether another cut is coming. The Q2 earnings report will be the next key event for investors.
This article is for informational purposes only and does not constitute investment advice.
